GlassScriptPhysician profile
Roman A Shingarev
NPI 1457564601
$2,172.94
in general payments reported to CMS, 2019-2025
21 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $438 · 2023: $245 · 2024: $836 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.85 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $305.40 | 2023-2025 | Tavneos, Krystexxa, Parsabiv |
| W. L. Gore & Associates, INC. | $213.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $210.41 | 2023-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $170.35 | 2023-2024 | Veltassa |
| Ardelyx, INC. | $137.02 | 2023-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $125.49 | 2023-2025 | Jynarque |
| Horizon Therapeutics Plc | $124.99 | 2022 | |
| Travere Therapeutics, INC. | $124.22 | 2023-2025 | |
| Lilly USA, LLC | $117.69 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $108.06 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $107.78 | 2021 | |
| Glaxosmithkline, LLC. | $99.39 | 2022 | |
| Calliditas Therapeutics US INC. | $64.22 | 2023-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $61.74 | 2024-2025 | Ultomiris |
| Novo Nordisk INC | $53.58 | 2025 | Rivfloza, Ozempic, Rybelsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $39.58 | 2024-2025 | Velphoro |
| Genzyme Corporation | $35.43 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.32 | 2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2025 | Jardiance |
| Nxstage Medical, INC. | $15.73 | 2024 | |
| Cormedix INC. | $13.58 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Shingarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.